Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

(2021) Nasser H. Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

(2020) Florian Guisier et al.   Journal of Thoracic Oncology

Targeting BRAF mutations in non-small cell lung cancer

(2020) Connor Gerard O’Leary et al.   Translational Lung Cancer Research

Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens

(2020) Yang Ma et al.   PATHOLOGY RESEARCH AND PRACTICE

Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC

(2020) Ibiayi Dagogo-Jack et al.   Journal of Thoracic Oncology

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

(2020) Sandra Ortiz-Cuaran et al.   CLINICAL CANCER RESEARCH

ALK Inhibitors in the Treatment of ALK Positive NSCLC

(2019) Muhammad Khan et al.   Frontiers in Oncology

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience

(2019) Karim Rihawi et al.   Journal of Thoracic Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

(2019) Kathryn C. Arbour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers

(2019) M. Offin et al.   Journal of Thoracic Oncology

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

(2018) Elizabeth Dudnik et al.   Journal of Thoracic Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies

(2015) Y. P. Mosse   CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

(2015) Zeynep Eroglu et al.   Therapeutic Advances in Medical Oncology

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer

(2013) S. Cardarella et al.   CLINICAL CANCER RESEARCH

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

(2013) Charles M. Rudin et al.   Journal of Thoracic Oncology

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY